Pfizer "regrets" offending Harvard students; FDA advisory panel talks Seroquel April 8;

> Pfizer issued a statement saying it regrets if anyone was offended when a company sales rep photographed Harvard Medical School students protesting industry influence on campus. Report

> To compete with Bristol-Myers Squibb and Sanofi-Avenits's clotbuster Plavix in Europe, Eli Lilly will need to mount an aggressive marketing campaign for its newly-approved-in-the-EU drug Prasugrel, industry experts said. Report 

> The FDA will ask an advisory panel for advice on whether the agency should allow wider use of AstraZeneca's Seroquel, which is currently approved to treat bipolar disorder and schizophrenia; the meeting is tentatively scheduled for April 8. Report

> Teva Pharmaceutical has seen big growth in prescriptions of its Parkinson's treatment Azilect as neurologists get more comfortable with the drug, a Decision Resources study found. Report

> Pharmacies around the country are offering free antibiotics to cash-strapped consumers, but public health officials say the incentives send the wrong message and could worsen the problem of drug resistance. Report

> Left reeling from the FDA's rejection of its imaging drug in December, Acusphere is chopping 40 jobs--roughly two thirds of its remaining staff--in a restructuring that also includes the close of its Watertown, MA headquarters. Report

> Alnylam Pharmaceuticals and Isis Pharmaceuticals have chipped in $20 million to fund the Series A round of Regulus Therapeutics, their RNA spin-off. Report

> A struggling Pharmexa and Affitech have struck a deal to merge into a new company that will focus on new antibody therapeutics. Report

> With its closely-watched hep C drug telaprevir working its way toward an FDA filing, Vertex Pharmaceuticals announced that it is buying Canada's ViroChem Pharma for $375 million in cash and stock. Report

> Index Ventures has just closed a $438.8 million fund, with a big chunk of that slated for biotech companies with a lot to offer in the pipeline. Report

> A team of researchers led by Scripps Professor Carlos Barbas, III, Ph.D., report a new method of vaccination can provide instant protection against a pathogen. Report

> FluMist just got a big thumb's down in a study reviewing vaccine response in more than a million U.S. soldiers. Report

And Finally... Curious how Roche handles IT? Check out this podcast with its CIO. Report